Radius Health (RDUS) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Radius Health Reports Second Quarter 2016 Financial and Operating Results
August 4, 2016 6:31 AM EDTRadius NDA for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis was accepted for filing by FDA with a PDUFA date of March 30, 2017
An oral presentation on the clinical development progress of an optimized abaloparatide transdermal patch has been accepted as an oral Late-Breaker at ASBMR on September 19, 2016
Radius provides update on RAD1901 and RAD140 development programs
WALTHAM, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Radius or the Company) (Nasdaq: RDUS), a science-driven biopharmaceutical company that is committed to... More
